Exact Sciences Corporation: Is The Oncology Product Pipeline Development to Capture A Lion’s Share of the Market?

Exact Sciences recently reported its fourth-quarter 2024 financial results, showcasing a mix of both positive momentum and certain challenges. For the full year, Exact Sciences achieved a core revenue growth of 11%, reaching $2.75 billion, and notably expanded its adjusted EBITDA by nearly 48%. The company also doubled its free cash flow and ended the year with a robust $1.04 billion in cash and securities. This financial stability allowed the company to repay $250 million in maturing convertible notes, further strengthening its balance sheet.